Stockscreener 앱 받기
1.28
1.59%
0.02
시간 외 거래:
1.21
-0.07
-5.47%
전일 마감가:
$1.26
열려 있는:
$1.21
하루 거래량:
472.70K
Relative Volume:
0.25
시가총액:
$3.76M
수익:
-
순이익/손실:
$-17.06M
주가수익비율:
-0.0181
EPS:
-70.7173
순현금흐름:
$-14.18M
1주 성능:
+12.28%
1개월 성능:
+56.08%
6개월 성능:
-75.64%
1년 성능:
-99.77%
1일 변동 폭
$1.17
$1.34
1주일 범위
$1.06
$2.8999
52주 변동 폭
$0.7715
$800.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
명칭
Cns Pharmaceuticals Inc
전화
1-800-946-9185
주소
2100 WEST LOOP SOUTH, HOUSTON
CNSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
1.28 | 3.36M | 0 | -17.06M | -14.18M | -70.72 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 개시 | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer - The Globe and Mail
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved - Asianet Newsable
CNS Pharmaceuticals (CNSP) Advances in Neuro-Oncology with Promi - GuruFocus
CNSP Secures Funding to Support Operations Through 2026 | CNSP S - GuruFocus
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Secures $18M War Chest to Advance Breakthrough Brain Cancer Treatment - Stock Titan
CNS Pharmaceuticals Raises $5M in Public Offering - TipRanks
CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor - The Globe and Mail
Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize
CNS Pharmaceuticals sets terms for $5 million stock offering By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications - Barchart.com
CNS Pharmaceuticals Soars Over 100% on $5 Million Offering: What’s Driving the Surge? - RagingBull
CNS Pharmaceuticals sets terms for $5 million stock offering - Investing.com
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offer - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Stock Titan
CNSP Gains Key Orphan Drug Designation Transfer for TPI 287 | CN - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma - marketscreener.com
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | CNSP Stock News - GuruFocus
CNS Pharmaceuticals secures orphan drug status for cancer drug - Investing.com Australia
CNS Pharmaceuticals secures orphan drug status for cancer drug By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Yahoo Finance
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Medical Patent Injunction At Odds With Hatch-Waxman, Federal Circuit Finds - Law360
Press Release Distribution & PR Platform - ACCESS Newswire
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
CNS Pharmaceuticals Advances TPI 287 for Glioblastoma - TipRanks
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 - BioSpace
Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World
Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com
CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year - Yahoo Finance
CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Yahoo Finance
CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CNS Pharmaceuticals Inc. (CNSP) reports earnings - qz.com
CNS Pharmaceuticals (NASDAQ:CNSP) Receives Hold Rating from Maxim Group - Defense World
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance
Market Sentiment Around Loss-Making CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - simplywall.st
CNSP stock touches 52-week low at $1.49 amid sharp annual decline By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects - AInvest
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CNSP stock touches 52-week low at $1.49 amid sharp annual decline - Investing.com
CNS Pharmaceuticals shares tumble after clinical trial results By Investing.com - Investing.com South Africa
CNS Pharmaceuticals shares tumble after clinical trial results - Investing.com India
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - Yahoo Finance
CNS Pharmaceuticals expands stock sale agreement to $43.5 million - Investing.com
CNS Pharmaceuticals expands stock sale agreement to $43.5 million By Investing.com - Investing.com UK
The International Society for CNS Drug Development (ISCDD) Honors Sharon Mates, PhD, and Steven Paul, MD with Prestigious Leadership Award at 23rd Annual Meeting - Yahoo Finance
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan
Cns Pharmaceuticals Inc (CNSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):